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The PROFI Study (Prevention of Cerebral Embolization
by Proximal Balloon Occlusion Compared to
Filter Protection During Carotid Artery Stenting)
A Prospective Randomized Trial
Klaudija Bijuklic, MD, Andreas Wandler, MD, Fadia Hazizi, MD, Joachim Schofer, MD, PHD
Hamburg, Germany
Objectives The objective of this study was to compare the cerebral embolic load of filter-protected versus proximal balloon–
protected carotid artery stenting (CAS).
Background Randomized trials comparing filter-protected CAS with carotid endarterectomy revealed a higher periprocedural
stroke rate after CAS. Proximal balloon occlusion may be more effective in preventing cerebral embolization dur-
ing CAS than filters.
Methods Patients undergoing CAS with cerebral embolic protection for internal carotid artery stenosis were randomly as-
signed to proximal balloon occlusion or filter protection. The primary endpoint was the incidence of new cerebral
ischemic lesions assessed by diffusion-weighted magnetic resonance imaging. Secondary endpoints were the
number and volume of new ischemic lesions and major adverse cardiovascular and cerebral events (MACCE).
Results Sixty-two consecutive patients (mean age: 71.7 years, 76.4% male) were randomized. Compared with filter pro-
tection (n  31), proximal balloon occlusion (n  31) resulted in a significant reduction in the incidence of new
cerebral ischemic lesions (45.2% vs. 87.1%, p  0.001). The number (median [range]: 2 [0 to 13] vs. 0 [0 to 4],
p  0.0001) and the volume (0.47 [0 to 2.4] cm3 vs. 0 [0 to 0.84] cm3, p  0.0001) of new cerebral ischemic
lesions were significantly reduced by proximal balloon occlusion. Lesions in the contralateral hemisphere were
found in 29.0% and 6.5% of patients (filter vs. balloon occlusion, respectively, p  0.047). The 30-day MACCE
rate was 3.2% and 0% for filter versus balloon occlusion, respectively (p  NS).
Conclusions In this randomized trial of patients undergoing CAS, proximal balloon occlusion as compared with filter protec-
tion significantly reduced the embolic load to the brain. (J Am Coll Cardiol 2012;59:1383–9) © 2012 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.035Stroke is the third leading cause of death in industrialized
countries and the major cause of functional impairment (1).
Carotid artery stenosis is an important cause of stroke (2).
Carotid endarterectomy (CEA) has been established as an
effective treatment for symptomatic as well as for asymp-
tomatic patients (3). Carotid artery stenting (CAS) has
emerged as an alternative to CEA (4). Current data support
the use of embolic protection devices for CAS (5). Ran-
domized trials comparing CAS with CEA revealed lower
periprocedural stroke rates with surgery (6–10). As protec-
tion devices for CAS, filters were used in these trials.
From the Medical Care Center Prof. Mathey, Prof. Schofer, Hamburg University
Cardiovascular Center, Hamburg, Germany. The authors have reported that they
have no relationships relevant to the contents of this paper to disclose.Manuscript received September 19, 2011; revised manuscript received November 23,
2011, accepted November 29, 2011.Proximal balloon occlusion is an alternative to filter
protection, which, by occluding the external and common
carotid artery (CCA), induces reversed flow in the target
vessel before the lesion is crossed and stented. Whether this
results in a more effective cerebral embolic protection than a
filter device has never to our knowledge been studied in a
See page 1390
randomized trial. Diffusion-weighted magnetic resonance
imaging (DW-MRI) has been shown to be a sensitive tool
in identifying new ischemic cerebral lesions caused by
emboli during CAS (11–13) and can therefore serve as a
surrogate endpoint. The primary objective of the present
study was to compare the incidence, the number, and
volume of new cerebral ischemic lesions after filter-
protected versus proximal balloon–protected CAS.
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Study design. The PROFI (Pre-
vention of Cerebral Embolization
by Proximal Balloon Occlusion
Compared to Filter Protection
During Carotid Artery Stenting)
study is a prospective randomized,
single-center trial. The study was
approved by the Freiburg ethics
committee (clinic trial code 010/
1707). At that time, the operator
had experience in CAS in more
than 1,000 patients. All patients
gave their written informed con-
sent. Between May 2010 and Au-
ust 2011, eligible patients were randomized in a 1:1 fashion to
et either filter or proximal balloon protection for the CAS
rocedure. Before and 12 to 24 h after CAS, a cerebral DW-
RI was performed.
The primary endpoint was the incidence of new cerebral
schemic lesions as assessed by DW-MRI. Secondary end-
oints were the number and volume of new cerebral ischemic
esions, major adverse cardiovascular and cerebral events
MACCE) (defined as death, stroke, myocardial infarction,
nd vascular complications) at 30 days, bleeding complications,
nd device crossover.
The inclusion and exclusion criteria are summarized in
able 1.
rocedure. Patients were on dual antiplatelet therapy (aspirin
00 mg and clopidogrel 75 mg/day) before the intervention
nd for 4 weeks after. Carotid artery stenting was performed by
single experienced operator (J.S.) (14) as described in detail
reviously (11). The protocol specified use of the Cristallo
deale stent (Invatec, Roncadelle, Italy), the Emboshield Pro-
ection System for filter protection (Abbott Vascular, Abbott
ark, Illinois), and the MO.MA ultra system (Invatec) for
roximal balloon occlusion, respectively.
iffusion-weighted magnetic resonance imaging. Cere-
ral DW-MRI scans were obtained before and 12 to 24 h
fter CAS using a 1.5-T scanner (Magnetom Sonata,
iemens, Erlangen, Germany). Images were reviewed by 2
ndependent physicians (A.W. and F.H.), both blinded to
he protection device used. Echo planar imaging with the
ollowing parameters was used: TR  3,000 ms, TE  84
s, 19 slices with a slice thickness of 6 mm, field of view 
30 mm, diffusion values b  0, 500, 1,000 s/mm2, fat
aturation, time of acquisition  71 s. Additionally, appar-
nt diffusion coefficient maps were obtained. A new lesion
fter CAS was defined as a focal hyperintense area detected
y the fluid-attenuated inversion recovery sequence, corre-
ponding to a restricted diffusion signal in the diffusion-
eighted imaging sequence, confirmed by apparent diffu-
ion coefficient mapping to rule out a shine-through artifact.
he number, volume, and location of new ischemic lesions
Abbreviations
and Acronyms
CAS  carotid artery
stenting
CCA  common carotid
artery
CEA  carotid
endarterectomy
DW-MRI  diffusion-
weighted magnetic
resonance imaging
MACCE  major adverse
cardiovascular and cerebral
eventsn DW-MRI at follow-up were assessed.ollow-up assessments. Patients underwent neurological
xamination by an independent neurologist prior to carotid
rtery stenting and before discharge and were monitored for at
east 24 h. A follow-up visit with neurological evaluation and a
uplex ultrasound of the target vessel was scheduled at 30 days.
efinitions. Patients were considered symptomatic if they
ad an ipsilateral neurological ischemic event within 6
onths before the procedure.
Diameter stenosis for patient screening was determined
y ultrasound using the peak systolic velocity ratio, the ratio
f the peak systolic velocity in the internal carotid artery to
he peak systolic velocity in the distal CCA, with a value of
2.0 for 50% stenosis, 4.0 for 70% stenosis with the
dditional value of 5.0 for 90% stenosis but less than near
cclusion. Diameter stenosis for evaluation of the proce-
ural result was determined angiographically by visual
stimate before and after stenting.
Procedural success was defined as residual stenosis after
tenting 30% and the absence of complications.
Stroke was defined as a new neurological deficit with focal
ymptoms and signs consistent with focal cerebral ischemia,
asting at least 24 h. Stroke was considered minor if a neurological
eficit resolved completely within 30 days or did not lead to an
mpairment in daily activities as judged by the independent
eurologist. Otherwise, stroke was defined as major.
Balloon intolerance was defined as transient neurological
ymptoms during balloon occlusion which promptly disap-
eared after balloon deflation.
Myocardial infarction was defined as an increase in
reatine kinase-MB 3 times the upper reference limit
Inclusion and Exclusion CriteriaTable 1 Inclusion and Exclusion Criteria
Inclusion criteria
Patient age 18 yrs
Symptomatic ICA stenosis 60% on ultrasonography
Asymptomatic ICA stenosis 80% on ultrasonography
No occlusion of the ipsilateral external carotid artery
Patent contralateral ICA
Complete circle of Willis (assessed by MR angiography)
Lesion passage with the filter possible without pre-dilation (assessed by MR
angiography)
Sufficient landing zone (4 cm) for the filter (assessed by MR angiography)
Patients provided written informed consent
Exclusion criteria
Ischemic stroke within previous 48 h
Total occlusion of the target vessel
Contraindication for MRI (pacemaker, claustrophobia)
Previous major stroke, severe enough to confound the assessment of
endpoints
Contraindications for antiplatelet and/or anticoagulant therapy
In-stent restenosis
Coagulation disorders
Gastric ulcer or gastrointestinal bleeding within the last 30 days
Untreated hyperthyreosis
Allergy to contrast agent, aspirin, or clopidogrelICA  internal carotid artery; MR  magnetic resonance; MRI  magnetic resonance imaging.
T
I
1385JACC Vol. 59, No. 15, 2012 Bijuklic et al.
April 10, 2012:1383–9 Embolic Protection in Carotid Artery Stentingcombined with electrocardiographic evidence of ischemia or
symptoms consistent with myocardial ischemia.
Bleeding complications were defined according to the
Thrombolysis In Myocardial Infarction criteria (15).
Cerebral ischemic lesions were defined as ipsilateral, if
present in the hemisphere supplied by the treated carotid
artery, otherwise as contralateral.
The type of aortic arch was defined as:
• Type I, if the vertical distance from the origin of the
innominate artery to the top of the arch is1 diameter
of the left CCA.
• Type II, if the vertical distance from the origin of the
innominate artery to the top of the arch is between 1
and 2 left CCA diameters.
• Type III, if the vertical distance from the origin of the
innominate artery to the top of the arch is 2 left
CCA diameters.
he level of stroke severity was measured by the National
nstitutes of Health Stroke Scale scoring system:
• 0  no stroke
• 1 to 4  minor stroke
Figure 1 Flow Chart of Patient Enrollment
ECA external carotid artery; ICA  internal carotid artery; VA vertebral artery.• 5 to 15  moderate stroke
• 16 to 20  moderate/severe stroke
• 21 to 42  severe stroke
Statistical analysis. Analyses were performed on the
intention-to-treat basis. Continuous variables were pre-
sented as mean  SD, and Mann-Whitney and Student t
tests were used, as appropriate. Categorical variables were
compared using Fisher exact test. For statistical analysis,
Prism 3.0 (GraphPad Software, La Jolla, California) was
used. Values of p  0.05 were considered to indicate
statistical significance.
Results
Characteristics of patients. Of 84 consecutive patients, 62
fulfilled the study criteria and were randomized to either
filter protection (n  31) or proximal balloon occlusion
(n  31) (Fig. 1).
Demographic, clinical, and lesion characteristics of the
patients, as summarized in Table 2, were not different
between the 2 groups. The type of aortic arch did differ
significantly between the groups (type I: 23% vs. 35%, type
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Embolic Protection in Carotid Artery Stenting April 10, 2012:1383–9II: 52% vs. 25%, and type III: 9% vs. 40% in the filter vs.
balloon occlusion group, respectively, p  0.03).
Procedural duration was significantly longer in the bal-
loon occlusion group compared with the filter group (30 
8 min vs. 22  7 min, p  0.003). Balloon intolerance was
bserved in 3 of 31 patients (6.5%); the procedure, however,
ould be concluded under cerebral protection in all cases. In
one of the patients did we have to cross over to the filter or
se a combination of a filter and a balloon.
The 22 patients who did not meet the inclusion criteria
ere entered in a registry and underwent the same protocol
ncluding the DW-MRI if not contraindicated. The reasons
or excluding patients from randomization are summarized
n Figure 1. Clinical and duplex ultrasound follow-up at 30
ays was performed in all patients. There were no clinical
vents after hospital discharge, and the stent was patent in
ll patients.
rimary endpoint. The incidence of new cerebral ischemic
esions per patients in DW-MRI was significantly higher in
he filter group compared with the balloon occlusion group
87.1% vs. 45.2%, p  0.001) (Fig. 2). Results for symp-
omatic, asymptomatic, and age 80 years patients are
hown in Figure 2. Lesions were located in the ipsilateral
emisphere in all patients with positive findings and, in
ddition, in the contralateral hemisphere in 29.0% of
atients in the filter group and in 6.5% of patients in the
Baseline CharacteristicsAccording to the Treatment GroupTable 2 B selin CharacteristicsAccording to the Treatment Group
Filter
(n  31)
Balloon Occlusion
(n  31) p Value
Baseline characteristics
Mean age, yrs 71.7 10.4 71.8 6.6 NS
80 yrs 26.0 13.0 NS
Male 77.4 77.4 NS
Diabetes 25.8 32.3 NS
Smoking 16.6 13.0 NS
Hypertension 96.8 100.0 NS
Dyslipidemia 90.4 77.4 NS
Symptomatic 38.7 41.9 NS
Coronary artery disease 64.5 48.4 NS
Lesion characteristics
Internal carotid artery, right 54.8 58.1 NS
Mean stenosis, pre-procedure 88.2 89.9 NS
Mean lesion length, mm 18.4 5.1 19.8 6.1 NS
Eccentric lesions 87.1 90.3 NS
Calcified lesions 61.3 67.7 NS
Ulcerated lesions 29.0 16.1 NS
Thrombotic lesions 0 0 NS
Bilateral stenoses 25.8 22.6 NS
De novo stenosis 96.7 100.0 NS
Procedural variables
Mean duration of procedure, min 22 7 30 8 0.003
Mean time of protection, min 5.26 1.8 5.98 1.9 NS
Values are mean  SD or %.alloon occlusion group (p  0.047).Secondary endpoints. The number of lesions per patient
was significantly higher in the filter compared with the
balloon occlusion group: 3.6  3.2 versus 1.0  1.4, p 
0.0001 (median [range]: 2 [0 to 13] vs. 0 [0 to 13]) (Fig. 3).
The volume of lesions per patient also differed signifi-
cantly (0.59  0.6 cm3 for the filter group vs. 0.16  0.2
m3 for the balloon occlusion group; p  0.0001), (median
[range]: 0.47 [0 to 2.4] cm3 vs. 0 [0 to 0.84] cm3) (Fig. 4).
The 30-day MACCE rate was 3.2% (n  1 with minor
troke, National Institutes of Health Stroke Scale of 1) in
he filter group and 0% in the balloon occlusion group (not
ignificant).
Bleeding or vascular complications were not observed in
ny patient.
One patient in the filter group crossed over to the balloon
cclusion group because of difficulty in placing the filter.
ne patient in the balloon occlusion group crossed over to
he filter group because the stiff wire could not be advanced
nto the external carotid artery.
esults of patients in the registry. Demographic and
linical characteristics of the patients entered into a
egistry, including age, percentage of patients age 80 years,
nd symptom status were not significantly different from
andomized patients. The incidence of bilateral CAS was
ignificantly higher in patients in the registry compared with
andomized patients (63.6% vs. 27.3%, p  0.002).
Of 22 patients, 20 underwent CAS under filter pro-
ection, 1 patient under balloon occlusion, and in 1
atient, no protection system was used. In 14 filter group
atients, a DW-MRI could be performed, revealing new
schemic lesions in 85.7% (12 of 14), which is comparable
o the group of patients randomized to filter protection
87.1%). One of the 22 patients experienced a minor
troke (4.5%).
Figure 2 Incidence of New Ischemic Lesions in Patients With
Filter Protection Versus Proximal Balloon Occlusion
In addition, symptomatic patients, asymptomatic patients, and patients 80
years of age are displayed.
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The major findings of the present study are:
1. In patients undergoing carotid artery stenting, proximal
balloon occlusion significantly reduces the incidence of
new cerebral ischemic lesions compared with filter pro-
tection as assessed by DW-MRI.
2. Also, the number and the volume of ischemic lesions are
significantly lower with proximal occlusion.
3. Eighty-three percent of patients who are candidates for
CAS are suitable for proximal balloon occlusion.
DW-MRI findings. To the best of our knowledge, this is
he first randomized trial comparing the effectiveness of
erebral embolic protection of a filter versus a proximal
alloon occlusion device in all-comer patients undergoing
AS. Cerebral embolization was assessed by DW-MRI,
hich has been shown to be a sensitive tool in identifying
Figure 3 Number of New Ischemic Lesions
per Patient Found in DW-MRI
(A) The number of ipsilateral and contralateral lesions, and the total number of
new ischemic lesions is shown. (B) Frequency distribution of the total number of
new ischemic lesions in patient with filter protection versus proximal balloon occlu-
sion. Filter protection (n  31), proximal balloon occlusion (n  31). DW-MRI 
diffusion-weighted magnetic resonance imaging.ew ischemic cerebral lesions caused by emboli during CAS(11–13). Cerebral ischemic lesions can be detected by DW-
MRI in patients undergoing cerebral angiography and CAS in
up to 70% of patients (16–18). This is well in accordance with
the incidence of new lesions in the present study.
To keep any potential bias as low as possible, the
procedure was performed by the same experienced operator,
by using the same stent, the same filter, and the same
proximal protection device. Variations of these factors could
impact the results (14,19). A significant reduction in the
incidence, the number, and the volume of new cerebral
ischemic lesions was found in patients who underwent CAS
with proximal balloon compared with filter protection. This
difference was independent of the symptom status of the
patients.
A recent study (20) supports our findings. In a subset of
patients with high-risk lipid-rich plaque, significantly lower
microembolic signal counts as assessed by transcranial
Doppler were found in the group of patients undergoing
Figure 4 Volume of New Ischemic Lesions
per Patient Found in DW-MRI
(A) Volume of ipsilateral and contralateral lesions, and total volume of new
cerebral lesions in patients with filter protection versus proximal balloon occlu-
sion. (B) Frequency distribution of total volume of new ischemic lesions in filter
versus balloon occlusion. Filter protection (n  31), proximal balloon occlusion
(n  31). DW-MRI  diffusion-weighted magnetic resonance imaging.
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tion (20).
Possible explanations for the differences in the efficacy of
embolic protection. Compared with balloon occlusion,
filters have some disadvantages. They have to cross the
lesion before the protection is installed, allow particles
smaller than their pore sizes (100 m) to pass through them
r, if not well adapted to the vessel wall, to pass along the
lter. Beyond that, filters can become overloaded with
ebris, with the risk of spilling the contents of the filter
uring retrieval, and they can occasionally be difficult to
etrieve (21,22).
A proximal protection system may be more effective in
reventing embolization, mainly because it is placed and
unctioning before the lesion is crossed, and induces re-
ersed flow by occluding both the external carotid artery and
he CCA. In contrast to filters, cerebral protection is kept in
lace as long as the aspirated blood, which is flushed
hrough a microporous filter, shows visible debris. In mul-
icenter registries, they result in 30-day rates of major
dverse events as low as 0.9% to 1.4% (23,24). Nonrandom-
zed comparisons using transcranial Doppler or DW-MRI
ere either in favor for proximal protection (25) or incon-
lusive (26,27). Randomized head-to-head comparisons of
lters versus proximal balloon occlusion have not been
erformed so far.
ontralateral new ischemic lesions. They most probably
riginate from the aortic arch. The carotid artery catheter-
zation technique has an impact on the incidence of new
schemic lesions in the contralateral hemisphere (28).
A lower number of contralateral lesions was found with
roximal balloon despite a more complex aortic arch,
erhaps as a result of a different approach to the target
arotid artery compared with a filter intervention. The
xternal carotid artery was wired first and then a dedicated
heath, which has a very soft tip and a smooth transition to
he bigger proximal part, was advanced over this wire,
voiding manipulations in the aortic arch. By contrast, for
lter positioning, a 5-F diagnostic catheter was loaded into
6-F long sheath and advanced into the target artery,
ollowed by the sheath, which then has to cross the aortic
rch. This may result in liberating more debris from the
ortic arch.
alloon intolerance. Balloon intolerance as a potential
rawback has been described elsewhere (29). Although
ontralateral occlusion is not a generally accepted contrain-
ication to balloon occlusion, we excluded those patients
rom the study in order to keep the incidence of balloon
ntolerance as low as possible. Despite this precaution,
alloon intolerance was observed in 13% of the patients in
he present study. Other known reasons for balloon intol-
rance are incomplete or aberrant circle of Willis, simulta-
eous intracerebral artery occlusive lesions, or poor collateral
ow. Pre-procedural imaging by MRI or transcranial
oppler can be useful in identifying these patients; how-ver, no study has proven to be completely reliable inredicting balloon intolerance. Also, in the present study,
re-procedural MRI could not identify all patients who
ould not tolerate balloon occlusion.
egistry data. Patients who did not meet the inclusion
riteria for the study went into the registry, thus the
rocedure and outcome data of all consecutive patients
ere collected. This provides the opportunity to analyze
he suitability for filter versus proximal balloon protection
n all-comer patients undergoing CAS. All patients in the
egistry were eligible for filter protection, whereas 15 of
2 patients, i.e., 17%, of the total patient cohort were not
uitable for proximal balloon protection. The incidence of
ew lesions in patients in the registry who received a filter
as comparable to the incidence of new lesions of the
atients randomized to the filter group, suggesting that
he randomized patients were not a highly selected group.
tudy limitations. This is a single-center study with a
imited number of patients. The endpoint of the study is
surrogate parameter instead of a clinical event. There
re differences in baseline patient (presence of coronary
rtery disease) and lesion characteristics (ulcerated steno-
is) that may have introduced bias in favor of proximal
rotection, yet the differences were not statistically sig-
ificant because of the small population sample. The
xtent of coronary artery disease may be a marker for
eneralized atherosclerosis, which may predispose pa-
ients to embolization from the arch. The complex type
f the aortic arch, however, was more often found in the
alloon occlusion group.
linical implications. Although the DW-MRI findings
ere mostly clinically unapparent, they are the tip of the
ceberg of what is happening to the brain during CAS. In
he present study, proximal balloon protection reduced the
ncidence of new ischemic lesions by a factor of 1.9.
hether the findings of the present study translate to a
ower stroke rate remains to be shown in a randomized trial
ith clinical endpoints.
onclusions
n this randomized trial of patients undergoing carotid
rtery stenting proximal balloon occlusion compared with
lter protection significantly reduces the embolic load to the
rain.
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